for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vascular Biogenics Ltd

VBLT.OQ

Latest Trade

1.84USD

Change

-0.13(-6.60%)

Volume

90,573

Today's Range

1.81

 - 

1.95

52 Week Range

0.91

 - 

3.17

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.97
Open
1.90
Volume
90,573
3M AVG Volume
22.01
Today's High
1.95
Today's Low
1.81
52 Week High
3.17
52 Week Low
0.91
Shares Out (MIL)
48.19
Market Cap (MIL)
89.15
Forward P/E
-3.42
Dividend (Yield %)
--

Next Event

Q4 2020 Vascular Biogenics Ltd Earnings Release

Latest Developments

More

VBL Therapeutics Says Data Safety Monitoring Committee Provides Green Light To Advance Oval Phase 3 Registration Enabling Study Of Vb-111 In Ovarian Cancer

VBL Therapeutics Reports Third Quarter 2020 Financial Results And Provides Corporate Update

Vbl Therapeutics Announces Q2 Loss Per Share $0.14

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vascular Biogenics Ltd

Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.

Industry

Biotechnology & Drugs

Contact Info

8 HaSatat St.

7178106

Israel

+972.8.9935000

http://www.vblrx.com

Executive Leadership

Bennett M. Shapiro

Non-Executive Independent Chairman of the Board

Dror Harats

Chief Executive Officer, Director

Amos Ron

Chief Financial Officer & Company Secretary

Eyal Breitbart

Vice President - Research and Operations

Erez Feige

Vice President - Business Operations

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.370

2018

-0.620

2019

-0.540

2020(E)

-0.540
Price To Earnings (TTM)
--
Price To Sales (TTM)
105.75
Price To Book (MRQ)
2.38
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
6.90
LT Debt To Equity (MRQ)
5.34
Return on Investment (TTM)
-52.83
Return on Equity (TTM)
-44.94

Latest News

Latest News

BRIEF-Vascular Biogenics files Prospectus Relates To Resale By Selling Shareholders Of Up To 11.5 Million Ordinary Shares That Are Issuable Upon Exercise Of Warrants

* VASCULAR BIOGENICS-PROSPECTUS RELATES TO RESALE BY SELLING SHAREHOLDERS OF UP TO 11.5 MILLION ORDINARY SHARES THAT ARE ISSUABLE UPON EXERCISE OF WARRANTS

BRIEF-VBL Presents Positive Interim Data From Pivotal Study In Ovarian Cancer

* VBL PRESENTS POSITIVE INTERIM DATA FROM THE OVAL PHASE 3 PIVOTAL STUDY IN OVARIAN CANCER AT THE ASCO20 ANNUAL MEETING, SHOWING 58% OR HIGHER OBJECTIVE RESPONSE RATE

BRIEF-Vbl Therapeutics To Present New Data On Its MOSPD2 Bispecific Antibody Program For Solid Tumors

* VBL THERAPEUTICS TO PRESENT NEW DATA ON ITS MOSPD2 BISPECIFIC ANTIBODY PROGRAM FOR SOLID TUMORS IN LATE BREAKING RESEARCH SESSION OF THE AACR VIRTUAL ANNUAL MEETING Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Vascular Biogenics Q1 Loss Per Share $0.15

* VBL THERAPEUTICS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-VBL First-In-Class Mospd2 Antibodies Show Potential For Treatment For Cns Inflammation

* VBL FIRST-IN-CLASS MOSPD2 ANTIBODIES SHOW POTENTIAL FOR TREATMENT FOR CNS INFLAMMATION Source text for Eikon: Further company coverage:

BRIEF-Vbl Therapeutics Announces New Milestone Event In The Vb-201 Collaboration For Veterinary Use

* VBL THERAPEUTICS ANNOUNCES NEW MILESTONE EVENT IN THE VB-201 COLLABORATION FOR VETERINARY USE

BRIEF-Vascular Biogenics Ltd Intends To Extend Ongoing Global Phase 3 Oval Clinical Trial In Ovarian Cancer To Patients In Japan

* VASCULAR BIOGENICS LTD - INTENDS TO EXTEND ONGOING GLOBAL PHASE 3 OVAL CLINICAL TRIAL IN OVARIAN CANCER TO PATIENTS IN JAPAN

BRIEF-VBL Therapeutics Announces Positive Outcome Of Interim Analysis In Oval Phase 3 Ovarian Cancer Pivotal Study

* VBL THERAPEUTICS ANNOUNCES POSITIVE OUTCOME OF INTERIM ANALYSIS IN OVAL PHASE 3 OVARIAN CANCER PIVOTAL STUDY

BRIEF-Vbl Therapeutics Announces Year Ended December 31, 2019 Financial Results And Provides Corporate Update

* VBL THERAPEUTICS ANNOUNCES YEAR ENDED DECEMBER 31, 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-VBL Therapeutics Announces The Launch Of A New Clinical Trial Of VB-111 Combined With The Checkpoint Inhibitor, Nivolumab, In Metastatic Colorectal Cancer

* VBL THERAPEUTICS ANNOUNCES THE LAUNCH OF A NEW CLINICAL TRIAL OF VB-111 COMBINED WITH THE CHECKPOINT INHIBITOR, NIVOLUMAB, IN METASTATIC COLORECTAL CANCER

BRIEF-Vbl Therapeutics Announces Q1 Loss Per Share $0.24

* VBL THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-VBL Therapeutics Awarded $2.5 Million Non Dilutive Grant By The Israel Innovation Authority

* VBL THERAPEUTICS AWARDED $2.5 MILLION NON-DILUTIVE GRANT BY THE ISRAEL INNOVATION AUTHORITY Source text for Eikon: Further company coverage:

BRIEF-VBL Therapeutics Announces Top-Line Results From Pivotal Phase 3 Globe Study In Patients With Recurrent Glioblastoma

* VBL THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PIVOTAL PHASE 3 GLOBE STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up